Robert Barrow - The Psychedelic Transformation - a podcast by LSE SU Entrepreneurs

The Bits & Bytes Series - Robert Barrow

Hosted by Sia Sha

Robert Barrow is the CEO of MindMed, a psychedelic biotech company founded in 2019. MindMed was the first psychedelic company that was listed on the Nasdaq and is currently in clinical trials - for example, for exploring the efficacy of LSD on generalised anxiety disorder. 🧠📚 The company has a market cap of roughly 700m and has received investment from individuals such as Kevin O’Leary. 🏋️‍♀️

Rethink your brain health:

https://mindmed.co/

Timestamps:

1:35 - What are psychedelics?

2:45 - Why are psychedelics controversial? Is the controversy based on valid concerns? 

7:25 - Has depression, anxiety, and disconnection been on the rise in recent years? Why is therapy not enough?

17:12 - Rob talks about his journey through MindMed, from a consultant to CEO, and the potential he saw in the company. 

31:39 - Rob discuss development of psychedelics and how they plan to take it to market.

32:05 - Are there any adverse effects of the usage of psychedelics? How does MindMed test for them? 

45:19 - How do psychedelics work on anxiety disorder?

1:00:00 - Rob discusses the end goal and vision of MindMed, and who he would like as colleagues in the company.

01:01:47 - Why did MindMed go public?

1:10:07 - Rob discuss planning for distribution channels

Further episodes of the talktank

Further podcasts by LSE SU Entrepreneurs

Website of LSE SU Entrepreneurs